Pharmacogenomics: translating functional genomics into rational therapeutics WE Evans, MV Relling science 286 (5439), 487-491, 1999 | 3365 | 1999 |
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression P Kuehl, J Zhang, Y Lin, J Lamba, M Assem, J Schuetz, PB Watkins, ... Nature genetics 27 (4), 383-391, 2001 | 2743 | 2001 |
Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling EJ Yeoh, ME Ross, SA Shurtleff, WK Williams, D Patel, R Mahfouz, ... Cancer cell 1 (2), 133-143, 2002 | 2420 | 2002 |
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia CG Mullighan, S Goorha, I Radtke, CB Miller, E Coustan-Smith, JD Dalton, ... Nature 446 (7137), 758-764, 2007 | 2176 | 2007 |
Acute lymphoblastic leukemia CH Pui, MV Relling, JR Downing New England Journal of Medicine 350 (15), 1535-1548, 2004 | 2014 | 2004 |
Deletion of IKZF1 and Prognosis in Acute Lymphoblastic Leukemia CG Mullighan, X Su, J Zhang, I Radtke, LAA Phillips, CB Miller, J Ma, ... New England Journal of Medicine 360 (5), 470-480, 2009 | 1710 | 2009 |
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia KG Roberts, Y Li, D Payne-Turner, RC Harvey, YL Yang, D Pei, ... New England journal of medicine 371 (11), 1005-1015, 2014 | 1543 | 2014 |
Treating childhood acute lymphoblastic leukemia without cranial irradiation CH Pui, D Campana, D Pei, WP Bowman, JT Sandlund, SC Kaste, ... New England Journal of Medicine 360 (26), 2730-2741, 2009 | 1455 | 2009 |
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros CG Mullighan, CB Miller, I Radtke, LA Phillips, J Dalton, J Ma, D White, ... Nature 453 (7191), 110-114, 2008 | 1232 | 2008 |
CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network MV Relling, TE Klein Clinical Pharmacology & Therapeutics 89 (3), 464-467, 2011 | 1164 | 2011 |
Childhood acute lymphoblastic leukemia: progress through collaboration CH Pui, JJ Yang, SP Hunger, R Pieters, M Schrappe, A Biondi, A Vora, ... Journal of Clinical Oncology 33 (27), 2938-2948, 2015 | 1034 | 2015 |
Moving towards individualized medicine with pharmacogenomics WE Evans, MV Relling Nature 429 (6990), 464-468, 2004 | 1005 | 2004 |
Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance CR Yates, EY Krynetski, T Loennechen, MY Fessing, HL Tai, CH Pui, ... Annals of internal medicine 126 (8), 608-614, 1997 | 989 | 1997 |
Pharmacogenomics in the clinic MV Relling, WE Evans Nature 526 (7573), 343-350, 2015 | 918 | 2015 |
Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing MV Relling, EE Gardner, WJ Sandborn, K Schmiegelow, CH Pui, SW Yee, ... Clinical Pharmacology & Therapeutics 89 (3), 387-391, 2011 | 897 | 2011 |
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia Y Liu, J Easton, Y Shao, J Maciaszek, Z Wang, MR Wilkinson, ... Nature genetics 49 (8), 1211-1218, 2017 | 894 | 2017 |
Mercaptopurine Therapy Intolerance and Heterozygosity at the Thiopurine S-Methyltransferase Gene Locus MV Relling, ML Hancock, GK Rivera, JT Sandlund, RC Ribeiro, ... Journal of the National Cancer Institute 91 (23), 2001-2008, 1999 | 870 | 1999 |
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there? CH Pui, CG Mullighan, WE Evans, MV Relling Blood, The Journal of the American Society of Hematology 120 (6), 1165-1174, 2012 | 776 | 2012 |
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment A Holleman, MH Cheok, ML den Boer, W Yang, AJP Veerman, ... New England Journal of Medicine 351 (6), 533-542, 2004 | 736 | 2004 |
Implementing genomic medicine in the clinic: the future is here TA Manolio, RL Chisholm, B Ozenberger, DM Roden, MS Williams, ... Genetics in Medicine 15 (4), 258-267, 2013 | 641 | 2013 |